Iron dextran

Modify Date: 2024-01-02 22:44:34

Iron dextran structure	Common Name	Iron dextran
	CAS Number	9004-66-4	Molecular Weight	1347.364
	Density	N/A	Boiling Point	N/A
	Molecular Formula	H₂O₄S_.Fe	Melting Point	N/A
	MSDS	USA	Flash Point	N/A
	Symbol	GHS07, GHS08	Signal Word	Danger

Use of Iron dextran

Iron dextran (Fe dextran) can be used in the study of iron-deficiency anemia in animals[1][2].

Name	Iron-dextran
Synonym	More Synonyms

Description	Iron dextran (Fe dextran) can be used in the study of iron-deficiency anemia in animals[1][2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
In Vivo	Iron dextran (FeDex, IP, 4 weeks, 300 μL of 10 mg) treatment does not increase NSR iron but causes iron-trapping in the tetinal vasculature[1]. Four weeks of IP FeDex injection in 2-month-old WT mice leads to iron accumulation in the RPE and rVECs, but did not increase NSR iron or induce photoreceptor degeneration[1]. Animal Model: Wild-type (WT) and RS-HepcKO mice[1]. Dosage: IP. Administration: 300 μL of 10 mg daily for 5 days each week for 2 or 4 weeks. Result: Markedly elevated iron levels in 2 and 4 weeks of FeDex-injection groups, by 365.4-fold and 405.4-fold, respectively, compared with PBS controls.
References	[1]. Wanting Shu, et al. Iron Accumulates in Retinal Vascular Endothelial Cells But Has Minimal Retinal Penetration After IP Iron Dextran Injection in Mice. Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4378-4387. [2]. D. R. ZIMMERMAN, et al. INJECTABLE IRON-DEXTRAN AND SEVERAL ORAL IRON TREATMENTS FOR THE PREVENTION OF IRONDEFICIENCY ANEMIA OF BABY PIGS x. Journal of Animal Science, Volume 18, Issue 4, November 1959, Pages 1409–1415.

Molecular Formula	H₂O₄S_.Fe
Molecular Weight	1347.364
Exact Mass	1346.576050
Appearance of Characters	solution

Symbol	GHS07, GHS08
Signal Word	Danger
Hazard Statements	H317-H350
Precautionary Statements	P201-P280-P308 + P313
Hazard Codes	Xn
Risk Phrases	R40;R42/43
Safety Phrases	S23;S26;S45;S36/S37/S39
RIDADR	NONH for all modes of transport
WGK Germany	-
RTECS	NI2200000

Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status

Exp. Hematol. 41(6) , 539-46, (2013)

Numerous studies have shown the antiproliferative effect of iron chelating agents (ICAs), which have been used traditionally in patients with secondary iron overload (SIO). Because the in vivo model f...

[Importance of the different i.v. iron generations for everyday medical practice].

MMW Fortschr. Med. 155 Suppl 1 , 18-24, (2013)

Iron deficiency and anaemia occur in particular in women or as comorbid conditions to a varietyof chronic diseases. Besides oral preparations, parenteral iron therapies are also available for the trea...

Use of intravenous iron supplementation in chronic kidney disease: an update.

Iran. J. Kidney Dis. 7(1) , 9-22, (2013)

Iron deficiency is an important clinical concern in chronic kidney disease (CKD), giving rise to iron-deficiency anemia and impaired cellular function. Oral supplementation, in particular with ferrous...

MFCD00081553

Ferric hydroxide dextran complex